Figure 2 | Scientific Reports

Figure 2

From: Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing

Figure 2

Sankey diagram representing the distribution of FDA drug approvals for which all trials included biomarker-positive patients (ie, enriched), the number of approvals with at least one non-enriched randomized controlled trial and the statistical significance of the treatment-by-biomarker interaction. Width of links is proportional to the number of approvals.

Back to article page